All In Biotech

Drug Trial Radar · NCT06800157

Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of LW402 Tablets in Patients With Moderate to Severe Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Feb 27, 2023

Primary completion

May 26, 2024

Study completion Aug 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase IIa study is designed to evaluate the dose-response relationship, efficacy, safety, and tolerability of LW402 tablets administered for 12 weeks in adult patients with active rheumatoid arthritis receiving background methotrexate (MTX) therapy.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • Drug: LW402Drug

    Oral tablets administered BID

  • Other: placeboDrug

    Placebo to match LW402 administered BID

  • MTXDrug

    Background treatment with MTX once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in DAS28-CRP at Week 12Time frame: 12 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.